Synergy Pharmaceuticals Inc.
SGYP, a developer of new drugs to treat gastrointestinal disorders
and diseases, today announced that it has signed an Asset Purchase Agreement
with Bristol-Myers Squibb Company BMY and has acquired the assets
related to FV-100, an orally available nucleoside analogue, currently being
developed for the treatment of shingles, a severe, painful skin rash caused by
reactivation of the varicella zoster virus – the virus that causes chickenpox.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in